[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363328-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363328-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-associated-fibroblast-targeting-therapies-as-a-tool-to-enhance-responses-to-radiotherapy-and-immunotherapy","Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy","","Cancer-associated fibroblasts (CAFs) are major components of the tumor microenvironment in solid tumors, supporting growth and immune evasion through persistent activation, extensive extracellular matrix remodeling, and secretion of growth factors, cytokines, and chemokines. CAFs correlate with poor responses to standard therapy and immunotherapy, yet their heterogeneity complicates understanding. Emerging strategies aim to target CAFs—through depletion, reprogramming, antibodies/cytokines, and radionuclides—alone or combined with radiotherapy, supported by strong preclinical evidence and early-phase clinical data.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-associated-fibroblast-targeting-therapies-as-a-tool-to-enhance-responses-to-radiotherapy-and-immunotherapy/363328/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-associated-fibroblast-targeting-therapies-as-a-tool-to-enhance-responses-to-radiotherapy-and-immunotherapy/363328.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are cancer-associated fibroblasts (CAFs) important for therapy outcomes?","Question",{"text":63,"@type":64},"CAFs actively remodel the tumor microenvironment, promoting proliferation and immunosuppression. Their abundance is linked to poor prognosis and reduced clinical responses to standard therapy and immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What have new technologies contributed to understanding CAFs?",{"text":68,"@type":64},"Single-cell RNA sequencing and spatial transcriptomics have revealed substantial CAF heterogeneity. They also clarify distinct CAF subsets and their functional roles in immune modulation and extracellular matrix organization.",{"name":70,"@type":61,"acceptedAnswer":71},"What strategies are discussed for targeting CAFs with or without radiotherapy?",{"text":72,"@type":64},"The document summarizes approaches including CAF depletion, reprogramming, CAF-directed antibodies and cytokines, and CAF-directed radionuclides. It also describes their use in combination with radiotherapy to enhance therapeutic responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363328,1791135746,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Review  \n Cancer-associated fibroblast targeting  \ntherapies as a tool to enhance responses to radiotherapy and immunotherapy  \nEneko Garate-Soraluze  ,1 Iñigo Martinez-Zubiaurre,2 Maria E Rodriguez-Ruiz  1,3  \nTo cite: Garate-Soraluze E, Martinez-Zubiaurre I, Rodriguez-Ruiz ME. Cancerassociated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy. Journal for ImmunoTherapy of Cancer 2026;14:e009702 . doi:10 . 1136/ jitc-2024-009702  \nAccepted 27 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Program of Immunology and Immunotherapy, Centro de Investigacion Medica Aplicada, Pamplona, Spain 2Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway  \n3Radiation Oncology, Clinica Universidad de Navarra Departamento de Oncologia Medica, Pamplona, Spain  \nCorrespondence to  \nDr Maria E Rodriguez-Ruiz; [mrruiz@unav.es](mrruiz@unav.es)  \nABSTRACT  \nCancer-associated fibroblasts (CAFs) are one of the main components of the tumor microenvironment (TME) of solid tumors. They have several functions, which all contribute to tumor growth and immune evasion. CAF presence is associated with poor clinical response to standard therapy and immunotherapy. However, its heterogeneity blunts their understanding and functionality. New analytical techniques are being applied to better understand their role in cancer. Meanwhile, CAF stratification and their immunomodulatory capabilities are the scope of many studies, also in the context of ionizing irradiation. In that regard, new immunotherapy strategies have set their sights on targeting CAF to modulate the TME into a more immune-stimulating environment. Among the different approaches, CAF depletion, reprogramming, and CAFdirected antibodies and cytokines can be distinguished, supported by substantial preclinical evidence and encouraging, but still preliminary clinical findings, mainly from early-phase (phase I) trials. Additionally, CAF-directed radionuclides have gained interest and are in clinical trials for therapeutic as well as diagnostic purposes. Here we summarize the studies and clinical developments of CAF-targeted therapies alone and in combination with radiotherapy.  \nINTRODUCTION  \nCancer-associated fibroblasts (CAFs) are keystromal components of the tumor microenvironment (TME) that profoundly influence cancer progression and therapeutic outcomes.1 2 Unlike normal fibroblasts, CAFs exhibit a persistently activated phenotype,3 characterized by extensive extracellular matrix (ECM) remodeling and secretion of abroad repertoire of growth factors, cytokines, and chemokines.4 Through these functions, CAFs promote tumor proliferation, angiogenesis, invasion, and metabolic adaptation, ultimately fostering a protumorigenic and immunosuppressive milieu.5 6 High CAF abundance has been consistently associated with poor prognosis across multiple cancer types, underscoring their central role in tumor maintenance and resistance to therapy.  \nRecent advances in single-cell RNA sequencing and spatial transcriptomics have revealed remarkable CAF heterogeneity across and within tumor types, reflecting their diverse origins, phenotypes, and functions.7 Distinct subsets—such as myofibroblastic (myCAFs), inflammatory (iCAFs), and antigen-presenting—exert specialized roles in ECM organization, cytokine signaling, and immune modulation.8 Importantly, CAF phenotypes are dynamic and can shift in response to environmental and therapeutic pressures, including exposure to cytotoxic treatments.9 This functional versatility suggests that CAFs may not only survive conventional anticancer therapies but also actively contribute to treatment resistance, particularly to radiotherapy and immunotherapy.  \nCAFs are pivotal regulators of the TME, orchestrating ECM remodeling, immunosuppression, and therapy resistance. Their marke","cbCaitioMyQW2iFJ","https://ap.wps.com/l/cbCaitioMyQW2iFJ","pdf",2007607,15,"English","# Abstract\n# Introduction\n## CAF roles in tumor progression and therapy resistance\n## CAF heterogeneity and dynamic phenotypes\n## Translational challenges and targeting strategies","[{\"question\":\"Why are cancer-associated fibroblasts (CAFs) important for therapy outcomes?\",\"answer\":\"CAFs actively remodel the tumor microenvironment, promoting proliferation and immunosuppression. Their abundance is linked to poor prognosis and reduced clinical responses to standard therapy and immunotherapy.\"},{\"question\":\"What have new technologies contributed to understanding CAFs?\",\"answer\":\"Single-cell RNA sequencing and spatial transcriptomics have revealed substantial CAF heterogeneity. They also clarify distinct CAF subsets and their functional roles in immune modulation and extracellular matrix organization.\"},{\"question\":\"What strategies are discussed for targeting CAFs with or without radiotherapy?\",\"answer\":\"The document summarizes approaches including CAF depletion, reprogramming, CAF-directed antibodies and cytokines, and CAF-directed radionuclides. It also describes their use in combination with radiotherapy to enhance therapeutic responses.\"}]","Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy | PDF",1790150823,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf3f58b0731606fddc058d8f4f97f7fb.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cdafc4b6f198ad13b7206015136d4fcc.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90c9a600fbfd69fc5857240a192763b0.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc6c4cbc8484a9b11b0b247db2b7b13c.webp",980,1306]